Best Audio Medica Podcasts (2024)

1
Low Rates of Early Detection Drive Excess Breast Cancer Mortality in Underserved Communities 24:31

12M ago24:31

24:31

BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United Kingdom and Nigeria. A range of low cost community-based interventions could be used to modify these drivers, the research concludes. Huge reductions of b…

1
AUDIO JOURNAL OF ONCOLOGY—Options Identified for Chemotherapy Intensity Reduction in Acute Lymphoblastic Leukemia 13:34

1y ago13:34

13:34

Audio Journal of Oncology, February 14 2023,Â Reporting from the American Society of Hematology Annual Meeting (ASH), December 2022 An interview with Amy A. Kirkwood MSc,Â Senior Statistician at the Cancer Research UK & UCL Cancer Trials Centre, University College, London, UK Interviewer: Peter M Goodwin TITLE: Options Identified for in Acute Lymph…

1
AUDIO JOURNAL OF ONCOLOGY—Don’t Delay Stem Cell Transplant For Patients with Relapsed or Refractory Acute Myeloid Leukemia 15:06

1y ago15:06

15:06

Interview with Matthias Stelljes MD, Head of the Allogeneic Stem Cell Program at the University of MÃ¼nster, Germany NEW ORLEANS, USA—For yourÂ patients with acute myeloid leukemia (AML) the benefit of prompt allogeneic hematopoietic cell transplantation (alloHCT) Â extends to those whose disease has relapsed or is refractory to induction therapy, …

1
AUDIO JOURNAL OF ONCOLOGY—Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma 16:28

1y ago16:28

16:28

Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma NEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best practice recommendations) could be treated as effectively—and potentially with less toxicity—with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutini…

1
AUDIO JOURNAL OF ONCOLOGY—Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma 20:54

1+ y ago20:54

20:54

January 10, 2023 Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma INTERVIEW WITH: Ajai Chari MD, Associate Professor of Medicine and Director of Clinical Research in the Multiple Myeloma Program at Mount Sinai School of Medicine in New York, USA. NEW ORLEANS, USA—The bispecific antibody talquetamab, cla…

1
AUDIO JOURNAL OF ONCOLOGY—High Response Rates in Lung Cancer from Next Generation ROS1 InhibitorÂ 12:07

1+ y ago12:07

12:07

An interview with: Byoung Chul Cho MD PhD, Thoracic Medical Oncologist, from the Yonsei Cancer Center at Yonsei University College of Medicine in Seoul, South Korea. BARCELONA, Spain—A “next generation” ROS1 tyrosine kinase inhibitor (TKI), repotrectinib—studied in the phase one/two Trident-1 study among patients whose advanced non-small cell lung …

1
AUDIO JOURNAL OF ONCOLOGY—ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy 13:59

1+ y ago13:59

13:59

ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine kinase—mutated in some cancers—were reported at the 2022 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics conference held in Barcelona. First…

1
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting Â was Safe and Effective in Phase One Study 10:16

1+ y ago10:16

10:16

Pan-AKT Inhibitor Tumor Agnostic Targeting Â was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor ipatasertib in a phase one study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarte…

1
AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses 9:13

1+ y ago9:13

9:13

BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and actual mechanisms for cancer inhibition.Â But it now looks as though MYC could be a viable target for cancer drugs. A phase one study of a “pan-MYC inhibitor” OMO…

1
AUDIO JOURNAL OF ONCOLOGY—New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma 17:40

1+ y ago17:40

17:40

New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma Interview with: Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona at Barcelona University, Spain. BARCELONA, Spain—A phase one study of new drug targeting the monopolar spindle 1 enzyme was found to be safe—with rever…

1
AUDIO JOURNAL OF ONCOLOGY—Cell Therapy Markedly Improved Outcomes After Immunotherapy in Melanoma 5:59

1+ y ago5:59

5:59

PARIS, France—Patients who had cell therapy as second-line treatment for their advanced melanoma lived twice as long without disease progression compared with those who merely continued with pure immunotherapy. This finding came from a phase three randomized study reported at the 2022 Congress of the European Society for Medical Oncology (ESMO) by …

1
AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting 8:33

1+ y ago8:33

8:33

BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. Karisa Schreck MD PhD, from Johns Hopkins Hospital, Baltimore, Maryland in the USA talked wi…

1
AUDIO JOURNAL OF ONCOLOGY—First Line Atezolizumab Extends Life in Unfit Patients with Lung Cancer 7:01

1+ y ago7:01

7:01

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were not fit enough to be recommended standard platinum doublet chemotherapy lived longer when treated with the programmed death-ligand 1 (PD-L1) inhibito…

1
AUDIO JOURNAL OF ONCOLOGY—Breast Conservation: Machine-Learning Helps De-Escalate Breast Cancer Therapy 8:14

1+ y ago8:14

8:14

HEIDELBERG, Germany—AndrÃ© Pfob, Clinical Research Assistant from the University Breast Unit at Heidelberg University Hospital, Germany tells the Audio Journal of Oncology’s correspondent Peter Goodwin about the machine learning techniques his group has been using to help identify patients who can be spared further treatment after neo-adjuvant ther…

1
AUDIO JOURNAL OF ONCOLOGY—PARP-Inhibition Beyond Initial Therapy Extends Life with Advanced Ovarian Cancer 6:09

1+ y ago6:09

6:09

PARIS, France—Long remissions and “potential cures” were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancers expressing the BRCA mutation who were treated with the poly ADP ribose polymerase (PARP) inhibitor olaparib after initial therapy. Â Two thirds of …

1
AUDIO JOURNAL OF ONCOLOGY—Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis 20:53

1+ y ago20:53

20:53

ATLANTA, USA—A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative neoplasm into acute myeloid leukemia. Findings from Oxford University in the UK (using the novel genetic sequencing tool called: single cell multi omics) were reported at the American Society…

1
AUDIO JOURNAL OF ONCOLOGY—“PM 2.5” Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer 7:14

1+ y ago7:14

7:14

PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of the European Society for Medical Oncology (ESMO). Charles Swanton FRCP BSc PhD, Professor and Senior Group Leader of the Francis Crick Institute, Consu…

1
Straight Talk with Dr. Brian J. Bolwell: Values 13:25

3+ y ago13:25

13:25

Welcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especially in academic medicine, consumed with values that are emotion-based? We will discuss these ideas and more with Dr. Brian J. Bolwell, the Chairman of the Taussig Cancer Institute and Professor of Med…

1
Straight Talk with Dr. Brian J. Bolwell: Moments 15:07

3+ y ago15:07

15:07

In his recurring Oncology Times column “Straight Talk: Today's Cancer Centers,” Brian J. Bolwell, MD dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell revisits his column “Moments,” and discusses how to foster vulnerability, create psychological safety on a team, and embrace joy.…

1
CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

4y ago

—

UK & NETHERLANDS—Following the the AJO Podcast interview with Professor Harry de Koning MD PhD, from the Erasmus University in Rotterdam, who discussed his research published in the New England Journal of Medicine that supports the widespread introduction of computed tomographic (CT) screening to detect lung cancer, this edition of the podcast hear…

1
Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent 16:39

4y ago16:39

16:39

Second Study Confirms Lung Cancer CT Screening Cuts Deaths NETHERLANDS—Erasmus University Medical Center, Rotterdam—Research published in the New England Journal of Medicine has confirmed the viability of computed tomographic (CT) screening for detecting cases of lung cancer early in high-risk individuals—namely those who smoke heavily and or have …

1
New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia 3:00

4y ago3:00

3:00

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclusions drawn from the Alliance North American Intergroup Study A041202 reported at the 2018 Annual Meeting of the American Society of Hematology (ASH). “Unless there…

1
Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation 10:00

4+ y ago10:00

10:00

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation The Audio Journal of Oncology Podcast SAN DIEGO—Overall survival after allogeneic hematopoietic cell transplantation (allo-HCT) was found to be adversely influenced by a lack of diversity in the intestinal microbiota—before, during and after the transplant—in a…

1
Genomic-led AML Clinical Decision Making Within Seven Days 11:00

4+ y ago11:00

11:00

Audio Journal of Oncology Reporting from 2018 annual meeting of the American Society of Hematology INTERVIEW WITH: John C. Byrd MD,Â Chief Medical Officer for the “Beat AML Trial” ,Â Chair of Leukemia Research, Â Senior Advisor for Cancer Experimental Therapeutics at Ohio State University Comprehensive Cancer Center,Â Columbus OH. SAN DIEGO, USA—In…

1
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia? 10:00

4+ y ago10:00

10:00

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 agent rituximab than patients in a control arm receiving standard fl…

1
Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

5+ y ago

—

MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and neck cancer who tested positive for human papilloma virus (HPV+) did better…

1
Which New Combination for Metastatic Renal Cell Cancer?

5+ y ago

—

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two different programmed death ligand 1 (PD…

1
Two Drug Combination Doubled Kidney Cancer Progression Free Survival

5+ y ago

—

MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib plus the anti-programmed death one ligand (PD-L1) avelumab in comparison w…

1
ALK—Targeted Lung Cancer Drugs Benefited Real World PatientsÂ

5+ y ago

—

MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry pick” patients to get statistically valid results. This is the conclusion …

1
First Line PARP Inhibition For Ovarian Cancer Assessed

5+ y ago

—

MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical Oncology (ESMO) in the light of findings from the SOLO1 randomized phase three trial in which there was more than a doubling of the numbers of patients …

1
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib

5+ y ago

—

BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled double-blind phase three SOLO1 study of women with newly diagnosed ovarian cancer who had BRCA1/2 mutations and were treated with the poly ADP ribose polymerase (…

1
PD-L1 Immunotherapy Delayed Triple Negative Breast Cancer Progression

5+ y ago

—

MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer in the randomized phase three IMpassion130 trial reported at the 2018 annual congress of the Eu…

1
Genomically Targeted Therapy Delays Advanced Breast Cancer Progression

5+ y ago

—

MUNICH—A combination of the phosphoinositide 3-kinaseÂ (PI3K) inhibitorÂ alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestrant in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2âˆ’) advanced breast cancer in the randomized phase th…

1
Palbociclib Combination Prolongs Life After Breast Cancer Hormone Therapy

5+ y ago

—

MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2âˆ’) advanced breast cancer who were treated with a combination of the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib in combination with fulvestrantlived longer than those receiving a placebo with fulvestrant in the prospective, ran…

1
Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer

5+ y ago

—

MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 annual congress of the European Society for Medical Oncology, ESMO. http://212.114.167.162/sl…

1
Pembrolizumab: No Survival Gains Second Line In Gastric Cancer

5+ y ago

—

Reporter: Sarah Maxwell BARCELONA—Pembrolizumab did not significantly improve overall survival (OS) or progression free survival (PFS) compared with paclitaxel as second-line therapy in patients with advanced gastric or gastro-esophageal junction cancer that had progressed after one line of chemotherapy (containing a platinum and fluoropyrimidine) …

1
Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib

5+ y ago

—

BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) whose disease had progressed despite sorafenib therapy in the phase 3 CELESTIAL trial reported to the 2018 ESMO World Congress on Gastrointesinal Cancer. http://as…

1
Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer

5+ y ago

—

BARCELONA—A chemotherapy combination consisting of trifluridine with tipiracil showed a “clinically meaningful and statistically significant” improvement in overall survival (OS) and progression free survival (PFS) compared with placebo in patients with heavily-pretreated metastatic gastric cancer (mGC) refractory to standard therapies in the rando…

1
Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin 8:54

5+ y ago8:54

8:54

CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized ASPECT multicenter study from the United Kingdom reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). The trial inve…

1
Preoperative Chemoradiotherapy Extends Survival in Pancreatic Cancer

5+ y ago

—

CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, multi…

1
Whole Genome Sampling Identifies Targetable Prostate Cancer Subgoups

5+ y ago

—

CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatthe 2018 Annual Meeting of the American Society of Clinical Oncology. (https://meetinglibrary.asco.org/record/160671/abstract) Lisanne F van Dessel MD, …

1
Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer

6y ago

—

CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported in a poster session at the 2018 Annual Meeting of the American Society of…

1
Superior Survival in Conservatively Treated Male Breast Cancer

6y ago

—

CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). https…

1
Gender Disparity in Head and Neck Cancer Treatment and Outcomes

6y ago

—

CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa Clara, California. The findings—using the generalized competing event (GCE) assessment model that balanced the risk of cancer death against non-cancer…

1
Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer 14:00

6y ago14:00

14:00

CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control group of patients receiving platinum-based chemotherapy in the open-label, phase…

1
Radiotherapy Cuts BRCA-Associated Contralateral Breast Cancer Risk 7:00

6y ago7:00

7:00

CHICAGO—Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA mutation-associated breast cancers in a study from Israel reported in a poster session at the American Society of Clinical Oncology 2018 annual meeting. h…

1
Handgrip Strength Predicts Survival in Elderly Patients with Lung Cancer 10:00

6y ago10:00

10:00

BARCELONA—Handgrip strength (HGS) was found to be an independent quantitative marker for overall survival among patients with early-stage non-small cell lung cancer (NSCLC) being treated with stereotactic body radiotherapy (SBRT) in a study discussed at the 2018 European Society for Radiotherapy & Oncology (ESTRO 37) conference. ABSTRACT: PV-0041 H…

1
Brachytherapy “Excellent” After Breast Conserving Surgery 14:00

6y ago14:00

14:00

BARCELONA—Accelerated partial breast irradiation (ABPI) brachytherapy completed in a single week gave at least as good efficacy and safety as other radiotherapy protocols after breast-conserving therapy (BCS) for patients with low-risk breast cancer and brought advantages in terms of symptoms and convenience in a randomized phase three trial(conduc…

1
Cervical Cancer: No Ureteral Stricture Increase With IG Brachytherapy 20:00

6y ago20:00

20:00

BARCELONA—Image-guided adaptive brachytherapy (IGABT) for patients with cervical cancer did not increase risk for ureteral stricture (a rare but feared complication of pelvic radiotherapy) in European research reported at the European Society for Radiotherapy & Oncology (ESTRO 37) 2018 conference. (OC-0072 Risk factors for ureteral stricture after …

Podcasts Worth a Listen

Audio Medica Podcasts

Podcasts Worth a Listen

Quick Reference Guide